Pradžia › Leukemija
Leukemija klinikiniai tyrimai JAV ieško dalyvių
102 tyrimai dėl Leukemija ieško dalyvių vietose visoje Jungtinėse Valstijose.
Miestai su daugiausia tyrimų
- Houston, TX28 tyrimai
- Boston, MA25 tyrimai
- New York City, NY19 tyrimai
- Los Angeles, CA16 tyrimai
- Chicago, IL16 tyrimai
- Durham, NC13 tyrimai
- Nashville, TN12 tyrimai
- Baldwin Park, CA12 tyrimai
- Columbus, OH12 tyrimai
- Philadelphia, PA12 tyrimai
- Milwaukee, WI11 tyrimai
- Atlanta, GA11 tyrimai
- Seattle, WA11 tyrimai
- Birmingham, AL10 tyrimai
- Aurora, CO10 tyrimai
- Edison, NJ9 tyrimai
- Mountain View, CA9 tyrimai
- Miami, FL9 tyrimai
- Cincinnati, OH9 tyrimai
- Portland, OR8 tyrimai
- Dallas, TX8 tyrimai
- Queens, NY8 tyrimai
- New Haven, CT8 tyrimai
- Buffalo, NY7 tyrimai
- Denver, CO7 tyrimai
- Orange, CA7 tyrimai
- Tampa, FL7 tyrimai
- Washington, DC7 tyrimai
- Clifton, NJ7 tyrimai
- Cedar Rapids, IA6 tyrimai
- Omaha, NE6 tyrimai
- Charlottesville, VA5 tyrimai
- Baltimore, MD5 tyrimai
- Ann Arbor, MI5 tyrimai
- Memphis, TN5 tyrimai
- Rochester, MN5 tyrimai
- San Diego, CA5 tyrimai
- Cleveland, OH5 tyrimai
- Charlotte, NC5 tyrimai
- Rochester, NY4 tyrimai
Pagal valstiją
- Ajova7 tyrimai
- Alabama10 tyrimai
- Arizona7 tyrimai
- Džordžija13 tyrimai
- Florida17 tyrimai
- Ilinoisas17 tyrimai
- Indianas4 tyrimai
- Kalifornija28 tyrimai
- Kanzasas5 tyrimai
- Kentukis6 tyrimai
- Koloradas15 tyrimai
- Konektikutas11 tyrimai
- Luiziana3 tyrimai
- Masčusetsas28 tyrimai
- Menas3 tyrimai
- Merilendas11 tyrimai
- Minesota9 tyrimai
- Misūris6 tyrimai
- Mičiganas8 tyrimai
- Nebraska6 tyrimai
- New Jersey15 tyrimai
- New Mexico3 tyrimai
- New York26 tyrimai
- North Carolina20 tyrimai
- Ohio26 tyrimai
- Oklahoma4 tyrimai
- Oregon9 tyrimai
- Pennsylvania15 tyrimai
- Rhode Island4 tyrimai
- South Carolina6 tyrimai
- Tennessee14 tyrimai
- Texas31 tyrimas
- Utah4 tyrimai
- Vermont4 tyrimai
- Virginia7 tyrimai
- Washington11 tyrimai
- Wisconsin13 tyrimai
Nesenai atnaujinti tyrimai
Oficialus tyrimo tekstas (anglų kalba)
Rutgers University Study of the Genetics of Blood Cancers
Renkami dalyviaiStebimasis tyrimasLaukiami sveiki savanoriai
Amžius nuo 18 iki 110 · Visoms lytims · Atnaujinta 2026-10-01 · NCT07714044Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Renkami dalyviaiStebimasis tyrimas
Amžius nuo 0 iki 38 · Visoms lytims · Atnaujinta 2026-10-01 · NCT06131801Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Renkami dalyviaiStebimasis tyrimas
Amžius nuo 18 iki 110 · Visoms lytims · Atnaujinta 2026-09-28 · NCT00923507Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
Renkami dalyviai3 fazė
Amžius nuo 18 iki 71 · Visoms lytims · Atnaujinta 2026-09-23 · NCT07504458Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
Renkami dalyviai2 fazė
Amžius nuo 1 iki 25 · Visoms lytims · Atnaujinta 2026-09-23 · NCT05645718Natural History Study of GATA2 Deficiency and Related Disorders
Renkami dalyviaiStebimasis tyrimasLaukiami sveiki savanoriai
Amžius nuo 2 iki 100 · Visoms lytims · Atnaujinta 2026-09-22 · NCT01905826A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Renkami dalyviai1/2 fazė
30 Days · Visoms lytims · Atnaujinta 2026-09-16 · NCT04065399Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)
Renkami dalyviai1 fazė
Iki 75 metų · Visoms lytims · Atnaujinta 2026-09-16 · NCT06345027Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-16 · NCT06824168A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
Renkami dalyviai1 fazė
Iki 25 metų · Visoms lytims · Atnaujinta 2026-09-15 · NCT06810583(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-15 · NCT04996875A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
Renkami dalyviai2 fazė
Amžius 12 ir vyresni · Visoms lytims · Atnaujinta 2026-09-11 · NCT06229912Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing
Renkami dalyviai
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-09 · NCT06907797Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
Renkami dalyviai3 fazė
Amžius nuo 18 iki 18 · Visoms lytims · Atnaujinta 2026-09-08 · NCT07509151Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-02 · NCT07249346Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Renkami dalyviai2 fazė
Amžius nuo 1 iki 18 · Visoms lytims · Atnaujinta 2026-09-02 · NCT07354074Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies
Renkami dalyviai1 fazė
Amžius nuo 1 iki 25 · Visoms lytims · Atnaujinta 2026-09-01 · NCT06408194First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-01 · NCT07586618Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy
Renkami dalyviaiStebimasis tyrimasLaukiami sveiki savanoriai
Amžius 5 ir vyresni · Visoms lytims · Atnaujinta 2026-08-31 · NCT05237986CIML NK Cells With Venetoclax for AML
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-28 · NCT06152809Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-28 · NCT07284433Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
Renkami dalyviai1 fazė
Amžius nuo 18 iki 90 · Visoms lytims · Atnaujinta 2026-08-26 · NCT07439211Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation
Renkami dalyviai1 fazė
18 Months – 39 Years · Visoms lytims · Atnaujinta 2026-08-21 · NCT07573111Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-20 · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-20 · NCT06001788Iš ClinicalTrials.gov, duomenys gauti 2026-10-04. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.